SG11202011270QA - Anti-cd3 antibodies and uses thereof - Google Patents

Anti-cd3 antibodies and uses thereof

Info

Publication number
SG11202011270QA
SG11202011270QA SG11202011270QA SG11202011270QA SG11202011270QA SG 11202011270Q A SG11202011270Q A SG 11202011270QA SG 11202011270Q A SG11202011270Q A SG 11202011270QA SG 11202011270Q A SG11202011270Q A SG 11202011270QA SG 11202011270Q A SG11202011270Q A SG 11202011270QA
Authority
SG
Singapore
Prior art keywords
antibodies
Prior art date
Application number
SG11202011270QA
Inventor
Francois Gaudet
Jill Giles-Komar
Bradley Heidrich
Chichi Huang
Colleen Kane
Ronan Mcdaid
Jennifer Nemeth-Seay
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of SG11202011270QA publication Critical patent/SG11202011270QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
SG11202011270QA 2018-05-24 2019-05-21 Anti-cd3 antibodies and uses thereof SG11202011270QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862676081P 2018-05-24 2018-05-24
PCT/IB2019/054188 WO2019224717A2 (en) 2018-05-24 2019-05-21 Anti-cd3 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
SG11202011270QA true SG11202011270QA (en) 2020-12-30

Family

ID=67211773

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011270QA SG11202011270QA (en) 2018-05-24 2019-05-21 Anti-cd3 antibodies and uses thereof

Country Status (25)

Country Link
US (2) US11603405B2 (en)
EP (1) EP3802608A2 (en)
JP (1) JP2021524249A (en)
KR (1) KR20210012007A (en)
CN (1) CN112912397A (en)
AR (1) AR115422A1 (en)
AU (1) AU2019274656A1 (en)
BR (1) BR112020023508A2 (en)
CA (1) CA3101271A1 (en)
CL (1) CL2020003033A1 (en)
CO (1) CO2020014506A2 (en)
CR (1) CR20200568A (en)
EA (1) EA202092847A1 (en)
EC (1) ECSP20075215A (en)
IL (1) IL278846A (en)
JO (1) JOP20200302A1 (en)
MA (1) MA52773A (en)
MX (1) MX2020012587A (en)
NI (1) NI202000089A (en)
PE (1) PE20210132A1 (en)
PH (1) PH12020551920A1 (en)
SG (1) SG11202011270QA (en)
TW (1) TW202012443A (en)
UY (1) UY38245A (en)
WO (1) WO2019224717A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017040344A2 (en) 2015-08-28 2017-03-09 Amunix Operating Inc. Chimeric polypeptide assembly and methods of making and using the same
CN110997725A (en) 2017-06-12 2020-04-10 蓝鳍生物医药公司 anti-IL 1RAP antibodies and antibody drug conjugates
BR112020023416A2 (en) 2018-05-24 2021-02-17 Janssen Biotech, Inc. monospecific and multispecific anti-tmeff2 antibodies and their uses
JOP20190116A1 (en) * 2018-05-24 2019-11-24 Janssen Biotech Inc Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
KR20210015902A (en) 2018-05-24 2021-02-10 얀센 바이오테크 인코포레이티드 PSMA binders and uses thereof
BR112021000186A2 (en) * 2018-07-19 2021-08-10 Regeneron Pharmaceuticals, Inc. bispecific anti-bcma x anti-cd3 antibodies and their uses
MX2021012767A (en) 2019-04-19 2021-11-18 Janssen Biotech Inc Methods of treating prostate cancer with an anti- psma/cd3 antibody.
KR20220040483A (en) * 2019-07-26 2022-03-30 얀센 바이오테크 인코포레이티드 Proteins comprising kallikrein-associated peptidase 2 antigen binding domains and uses thereof
US20220411504A1 (en) * 2020-05-27 2022-12-29 Janssen Biotech, Inc. Proteins comprising cd3 antigen binding domains and uses thereof
AR123083A1 (en) 2020-07-29 2022-10-26 Janssen Biotech Inc PROTEINS INCLUDING HLA-G ANTIGEN BINDING DOMAINS AND THEIR USES
US20230398147A1 (en) 2020-09-16 2023-12-14 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
US20240025992A1 (en) 2020-10-22 2024-01-25 Janssen Biotech, Inc. Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
US20230073821A1 (en) * 2021-08-27 2023-03-09 International Business Machines Corporation Antigen-binding proteins targeting coronavirus (cov) variants
WO2023178645A1 (en) * 2022-03-25 2023-09-28 嘉和生物药业有限公司 Cd3-targeting antibody and use thereof
US20240101691A1 (en) * 2022-09-21 2024-03-28 Sanofi Biotechnology Humanized anti-il-1r3 antibody and methods of use
WO2024077044A1 (en) 2022-10-05 2024-04-11 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3785186T2 (en) 1986-09-02 1993-07-15 Enzon Lab Inc BINDING MOLECULE WITH SINGLE POLYPEPTIDE CHAIN.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
PT1024191E (en) 1991-12-02 2008-12-22 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
AU9393398A (en) 1997-09-16 1999-04-05 Egea Biosciences, Inc. Method for the complete chemical synthesis and assembly of genes and genomes
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (en) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas TRANCHROMOSOMAL TRANSGEN RODENTS FOR THE MANUFACTURE OF HUMAN ANTIBODIES
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
CA2577082A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DE102005028778A1 (en) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Multi-layer foil, useful for lining a flexible container, comprises a barrier layer, a stretch-poor plastic layer, an antistatic plastic layer and a layer containing a safe material for food
AR060070A1 (en) 2006-03-24 2008-05-21 Merck Patent Gmbh HETERODYMERIC PROTEIN DOMAINS OBTAINED BY ENGINEERING
JP2009541275A (en) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス Production of bispecific antibodies
CN101952312A (en) 2007-07-31 2011-01-19 米迪缪尼有限公司 Multispecific epitope binding proteins and uses thereof
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
EP2231904B1 (en) 2007-12-19 2016-01-13 Janssen Biotech, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
JP2012505654A (en) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド Methods for humanizing and affinity maturating antibodies
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
KR101930964B1 (en) 2010-04-20 2018-12-19 젠맵 에이/에스 Heterodimeric antibody fc-containing proteins and methods for production thereof
DK2635607T3 (en) 2010-11-05 2019-11-18 Zymeworks Inc STABLE HETERODIMED ANTIBODY DESIGN WITH MUTATIONS IN THE FC DOMAIN
KR102060389B1 (en) 2011-05-21 2019-12-31 마크로제닉스, 인크. Cd3-binding molecules capable of binding to human and non-human cd3
ES2899956T3 (en) 2011-11-04 2022-03-15 Zymeworks Inc Stable heterodimeric antibody design with mutations in the Fc domain
JOP20200236A1 (en) * 2012-09-21 2017-06-16 Regeneron Pharma Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
CN104994729B (en) 2012-12-14 2019-01-11 Omt公司 Encode the polynucleotides with the rodent animal antibody of human idiotype and the animal comprising the polynucleotides
UA119646C2 (en) * 2013-07-05 2019-07-25 Ґенмаб А/С Humanized or chimeric cd3 antibodies
PE20210648A1 (en) * 2013-12-17 2021-03-26 Genentech Inc ANTI-CD3 ANTIBODIES AND METHODS OF USE
CA2942453A1 (en) * 2014-05-28 2015-12-03 F. Hoffmann-La Roche Ag Antibodies binding to human and cynomolgus cd3 epsilon
EP2982693A1 (en) * 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
ES2824167T3 (en) * 2015-01-23 2021-05-11 Sanofi Sa Anti-CD3 antibodies, anti-CD123 antibodies, and bispecific antibodies that specifically bind to CD3 and / or CD123
BR112018008908A2 (en) 2015-11-02 2018-11-27 Janssen Pharmaceutica Nv anti-il1rap antibodies, bispecific antigen-binding molecules that bind il1rap and cd3, and their uses
AU2017327723B2 (en) 2016-09-14 2022-11-17 Teneobio, Inc. CD3 binding antibodies
BR112020023187A2 (en) * 2018-05-16 2021-04-20 Janssen Biotech, Inc. methods for treating cancers and increasing the effectiveness of therapeutic t-cell redirecting agents
BR112020023416A2 (en) 2018-05-24 2021-02-17 Janssen Biotech, Inc. monospecific and multispecific anti-tmeff2 antibodies and their uses
JOP20190116A1 (en) 2018-05-24 2019-11-24 Janssen Biotech Inc Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
KR20210015902A (en) 2018-05-24 2021-02-10 얀센 바이오테크 인코포레이티드 PSMA binders and uses thereof

Also Published As

Publication number Publication date
EP3802608A2 (en) 2021-04-14
AU2019274656A1 (en) 2020-11-26
TW202012443A (en) 2020-04-01
MX2020012587A (en) 2021-04-28
WO2019224717A2 (en) 2019-11-28
MA52773A (en) 2021-04-14
KR20210012007A (en) 2021-02-02
PE20210132A1 (en) 2021-01-19
JOP20200302A1 (en) 2020-11-23
CR20200568A (en) 2021-02-26
NI202000089A (en) 2021-01-21
WO2019224717A3 (en) 2020-03-05
WO2019224717A9 (en) 2021-02-04
US11603405B2 (en) 2023-03-14
CA3101271A1 (en) 2019-11-28
CO2020014506A2 (en) 2020-12-10
US20230322924A1 (en) 2023-10-12
US20200048349A1 (en) 2020-02-13
CN112912397A (en) 2021-06-04
JP2021524249A (en) 2021-09-13
CL2020003033A1 (en) 2021-04-16
AR115422A1 (en) 2021-01-20
UY38245A (en) 2019-11-29
IL278846A (en) 2021-01-31
BR112020023508A2 (en) 2021-03-30
ECSP20075215A (en) 2020-12-31
PH12020551920A1 (en) 2021-06-14
EA202092847A1 (en) 2021-04-20

Similar Documents

Publication Publication Date Title
IL278846A (en) Anti-cd3 antibodies and uses thereof
IL276950A (en) Anti-cd73 antibodies and uses thereof
IL279974A (en) Bispecific anti-bcma x anti-cd3 antibodies and uses thereof
IL282968A (en) Anti-nkg2a antibodies and uses thereof
IL279455A (en) Anti-pd-1 antibodies and uses thereof
IL275734B (en) Anti-pd-l1 antibodies and uses thereof
SG11202105885WA (en) Anti-claudin antibodies and uses thereof
ZA202006066B (en) Anti-hla-g antibodies and use thereof
IL275826A (en) Anti-mct1 antibodies and uses thereof
IL281297A (en) Anti-npr1 antibodies and uses thereof
SG11202009772PA (en) Anti-dll3 antibodies and uses thereof
SG11202009625WA (en) Anti-trem-1 antibodies and uses thereof
IL280321A (en) Anti-cxcr2 antibodies and uses thereof
IL277330A (en) Anti-il-27 antibodies and uses thereof
IL282707A (en) Anti-tim-3 antibodies and their use
IL282708A (en) Anti-tim-3 antibodies and their use
IL283875A (en) Anti-il-27 antibodies and uses thereof
IL277075A (en) Anti-phf-tau antibodies and uses thereof
IL276548A (en) Bcma-binding antibodies and uses thereof
IL276675A (en) Anti-pd-1 antibodies and uses thereof
IL283926A (en) Anti-alpha-synuclein antibodies and uses thereof
IL281202A (en) Anti-tnfrsf9 antibodies and uses thereof
IL283890A (en) Anti-periostin antibodies and uses thereof
IL283180A (en) Anti-pd-1 antibodies and uses thereof
EP4041403A4 (en) Anti-kir3dl3 antibodies and uses thereof